Aduro Biotech and UC Berkeley Launch Industry-Leading Immunotherapeutics and Vaccine Effort
Aduro Biotech and University of California (UC) Berkeley collaboratively launched an Innovative Immunotherapeutic and Vaccine Research Initiative (IVRI) providing the access of Aduro’s technology platforms including LADD, STING Pathway Activators and B-select monoclonal antibodies to the researchers of UC Berkeley for the discovery and development of immunotherapeutics and strategic vaccines for deadly diseases like cancer, autoimmune diseases and other infectious diseases.
IVRI commenced to simultaneously manage and focus on the development of cancer and infectious disease research and to put forth some path breaking discoveries in both the fields. There is nothing better than your body’s own immune system kicking away all the anomalies from your body. UC Berkeley aims to engage the information and ideas accumulated by their previous research on cancer immunology, in this initiative to improve patient’s care and elevate their research network towards better understanding of immune system for treatment of cancer, infectious disease and autoimmune disease.
“Through this unique collaboration, there is tremendous opportunity to improve our understanding of the immune system’s potential to serve as an important weapon in treating cancer and infectious disease,” said Stephen T. Isaacs, chairman, president and CEO of Aduro Biotech. “By combining UC Berkeley’s leading research and academic resources with innovative technology platforms, such as those developed by Aduro, we are confident that this initiative will lead to an improved understanding of, and potential treatments for, some of the most devastating diseases.”
UC Berkeley will receive $7.5 million as research funding from the founding partner of IVRI, Aduro Biotech which could possibly be extended to an additional three years.
Immune system is the body’s indigenous powerful weapon against any disease. IVRI envisages that amplifying the basic understanding of immune recognition, cellular interactions and other elements of the immune system can empower us to make advancements in the treatment of many diseases. IVRI will serve as a platform for communication and collaboration among researchers, regulation of scientific and financial resources and in molding the ideas and findings for development of better therapies for human diseases.